RxDoctor Payments Data

Deborah Ruhlman

Gerontology · Charleston, WVNPI 1083019483

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 63.7% of it on its own, with 6 other manufacturers making up the rest.

$728in general payments, 2019–2025

Across 30 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$464
  • Novartis$103
  • Boston Scientific$86
  • Impulse Dynamics (USA) Inc.$25
  • Cardiva Medical, Inc.$19
  • Medtronic$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$71098%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gerontology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$26,133
Medicare patients
208
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban313$418,651
EntrestoSacubitril/Valsartan112$145,906
XareltoRivaroxaban101$128,285
JardianceEmpagliflozin54$74,548
Repatha SureclickEvolocumab39$28,304
FarxigaDapagliflozin Propanediol26$26,967
BrilintaTicagrelor19$13,394
Atorvastatin Calcium397$4,088
Metoprolol Succinate320$3,786
Dabigatran EtexilateDabigatran Etexilate Mesylate12$3,632
Losartan Potassium147$1,636
Ezetimibe45$1,626
Carvedilol178$1,590
Isosorbide Mononitrate ErIsosorbide Mononitrate100$1,429
Flecainide Acetate27$1,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$103$145,906112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other gerontology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →